Chickenpox: An update |
| |
| Authors: | Coralie Lo Presti Christophe Curti Marc Montana Charléric Bornet Patrice Vanelle |
| |
| Affiliation: | 1. Assistance publique–Hôpitaux de Marseille (AP–HM), pharmacie usage intérieur, hôpital Nord, Chemin-des-Bourrely, 13915 Marseille cedex 20, France;2. Assistance publique–Hôpitaux de Marseille (AP–HM), service central de la qualité et de l’information pharmaceutiques (SCQIP), hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France;3. Assistance publique–Hôpitaux de Marseille (AP–HM), pharmacie usage intérieur, hôpital de la conception, 147, boulevard Baille, 13005 Marseille, France;4. Laboratoire de pharmaco-chimie radicalaire, faculté de pharmacie, Aix-Marseille Université, CNRS, ICR, UMR 7273, 27, boulevard Jean-Moulin–CS30064, 13385 Marseille cedex 05, France |
| |
| Abstract: | Despite its benign characteristics, chickenpox is a childhood disease responsible for complications and deaths, particularly in the high-risk population. VariZIG®, not commercialized in France, is a good alternative for seronegative individuals exposed to the virus and not eligible for vaccination. The efficacy of routine vaccination has been demonstrated with a decrease in chickenpox incidence and with the development of herd immunity. Over time, the protective antibody titer of vaccinated people decreases and can be maintained by two doses of the vaccine. A tetravalent measles-mumps-rubella-chickenpox vaccine, used in the United States, has a good tolerability in spite of the occurrence of fever and febrile seizures. Routine vaccination would contribute to make savings in France, by reducing direct and indirect costs of chickenpox. |
| |
| Keywords: | Chickenpox Vaccination Varicelle Vaccination |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
